Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

Summary of Financial Statements for the Three Months Ended June 30, 2023 [IFRS] (Consolidated)

August 9, 2023

Company name: JMDC Inc.
Listing: Tokyo Stock Exchange
Stock code: 4483
URL: https://www.jmdc.co.jp/en/
Representative: Ryo Noguchi, President and CEO
Inquiries: Tomohiro Mochizuki, Senior Executive Officer and CFO
TEL: +81-3-5733-5010
Scheduled date to file quarterly securities report: August 14, 2023
Scheduled date to commence dividend payments: –
Preparation of supplementary material on quarterly financial results: Yes
Holding of quarterly financial results presentation meeting: None

(Yen amounts are rounded down to millions, unless otherwise noted.)

1. Consolidated financial results for the first three months of the fiscal year ending March 31, 2024 (from April 1, 2023 to June 30, 2023)

(1) Consolidated operating results (cumulative) (Percentages indicate year-on-year changes.)

	Revenue		Operating profit		Profit before tax		Profit	
Three months ended	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
June 30, 2023	6,698	16.0	2,546	135.5	2,552	127.8	2,040	168.5
June 30, 2022	5,776	27.5	1,081	31.3	1,120	38.8	759	41.0

	Profit attributable to owners of parent		Total comprehensive income		Basic earnings per share	Diluted earnings per share
Three months ended	Millions of yen	%	Millions of yen	%	Yen	Yen
June 30, 2023	2,040	166.5	2,043	167.8	32.42	31.07
June 30, 2022	765	42.1	762	41.7	13.55	12.73

Reference: EBITDA Three months ended June 30, 2023 ¥1,679 million [10.4%]
Three months ended June 30, 2022 ¥1,521 million [30.7%]

Note: EBITDA: Operating profit + Depreciation and amortization ± Other income and/or expenses

(2) Consolidated financial position

	Total assets	Total equity	Equity attributable to owners of parent	Ratio of equity attributable to owners of parent
As of	Millions of yen	Millions of yen	Millions of yen	%
June 30, 2023	97,523	65,841	65,856	67.5
March 31, 2023	98,567	64,524	64,539	65.5

2. Cash dividends

	Annual dividends				
	First quarter-end	Second quarter-end	Third quarter-end	Fiscal year-end	Total
	Yen	Yen	Yen	Yen	Yen
Fiscal year ended March 31, 2023	–	0.00	–	12.00	12.00
Fiscal year ending March 31, 2024	–				
Fiscal year ending March 31, 2024 (Forecast)		–	–	–	–

Note: Revisions to the forecast of cash dividends most recently announced: None

3. Consolidated earnings forecasts for the fiscal year ending March 31, 2024 (from April 1, 2023 to March 31, 2024)

(Percentages indicate year-on-year changes.)

	Revenue		Operating profit		Profit before tax		Profit		Profit attributable to owners of parent		Basic earnings per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
Fiscal year ending March 31, 2024	33,000	18.7	8,800	48.5	8,750	48.9	6,500	52.1	6,500	52.3	103.32

Note: Revisions to the earnings forecasts most recently announced: Yes

For details, please refer to “1. Qualitative information regarding financial results for the three months ended June 30, 2023 (3) Explanation of consolidated earnings forecasts and other forward-looking statements” on page 5 of the attached materials.

Reference: EBITDA Fiscal year ending March 31, 2024 ¥9,750 million [26.3%]

*** Notes**

(1) Changes in significant subsidiaries during the period (changes in specified subsidiaries resulting in the change in scope of consolidation): None

(2) Changes in accounting policies and changes in accounting estimates

(i) Changes in accounting policies required by IFRS: None

(ii) Changes in accounting policies due to other reasons: None

(iii) Changes in accounting estimates: None

(3) Number of issued shares (ordinary shares)

(i) Total number of issued shares at end of the period (including treasury shares)

As of June 30, 2023	62,977,408 shares
As of March 31, 2023	62,910,608 shares

(ii) Number of treasury shares at end of the period

As of June 30, 2023	614 shares
As of March 31, 2023	574 shares

(iii) Average number of shares outstanding during the period (cumulative from the beginning of the fiscal year)

For the three months ended June 30, 2023	62,939,621 shares
For the three months ended June 30, 2022	56,526,889 shares

*** Quarterly financial results reports are exempt from quarterly reviews conducted by certified public accountants or an audit corporation.**

*** Proper use of earnings forecasts, and other special items**

Notes on forward-looking statements

The forward-looking statements, including earnings forecasts, contained in these materials are based on information currently available to the Company and on certain assumptions deemed to be reasonable by the Company. Actual business and other results may differ substantially due to various factors. For details regarding matters related to earnings forecasts, please refer to page 5 of the attached materials.

How to obtain supplementary documents on financial results

Supplementary documents on financial results are released via TDnet on the same day.

Attached Material Index

1. Qualitative information regarding financial results for the three months ended June 30, 2023 2
(1) Explanation of operating results 2
(2) Explanation of financial position 4
(3) Explanation of consolidated earnings forecasts and other forward-looking statements 5
2. Condensed quarterly consolidated financial statements and significant notes thereto 6
(1) Condensed quarterly consolidated statement of financial position 6
(2) Condensed quarterly consolidated statement of profit or loss and condensed quarterly consolidated statement of comprehensive income 7
(3) Condensed quarterly consolidated statement of changes in equity 9
(4) Condensed quarterly consolidated statement of cash flows 11
(5) Notes to condensed quarterly consolidated financial statements 12
Notes on going concern assumption 12
Segment information 12
Significant subsequent events 13

1. Qualitative information regarding financial results for the three months ended June 30, 2023

(1) Explanation of operating results

JMDC Inc. (the "Company") is promoting the health of citizens, and delivering increased value of medical service providers and helping optimize their operations through gathering diverse data on the Japanese healthcare industry and thus benefiting society, with the aim of realizing a sustainable healthcare system by leveraging data and ICT.

In the Healthcare-Big Data segment, to promote the health services of health insurance associations, we provide analysis services for data held by payers as well as personal health record (PHR) services developed by the Company. We also provide services such as medical data analysis and medical factoring to medical institutions as well as medicine databases. Furthermore, we have created a database of anonymously processed information in the course of pursuing this business and are promoting scientific and industrial applications of this data.

In the Tele-medicine segment, we provide a matching service that connects medical institutions lacking a sufficient number of radiologists with contracted radiologists using a remote image interpretation system, as well as an ASP service that connects medical institutions with radiologists via the cloud to enable remote diagnostic imaging.

In the Dispensing Pharmacy Support segment, we develop and sell systems such as receipt computers and electronic medication history systems to health insurance pharmacies.

Operating results for the three months ended June 30, 2023 are as follows.

(Operating results)

(Millions of yen)

Category	10th fiscal year Three months ended June 30, 2022		11th fiscal year Three months ended June 30, 2023		YoY change	
Revenue	5,776		6,698		921	16.0%
Operating profit	1,081		2,546		1,464	135.5%
EBITDA [margin]	1,521	[26.3%]	1,679	[25.1%]	158	10.4%

(Segment results)

(Millions of yen)

Category		10th fiscal year Three months ended June 30, 2022		11th fiscal year Three months ended June 30, 2023		YoY change	
Healthcare-Big Data	Segment revenue	3,749		4,497		747	19.9%
	Segment profit [ratio]	1,124	[30.0%]	1,294	[28.8%]	170	15.1%
Tele-medicine	Segment revenue	1,175		1,307		131	11.2%
	Segment profit [ratio]	439	[37.4%]	448	[34.3%]	9	2.1%
Dispensing Pharmacy Support	Segment revenue	910		969		59	6.5%
	Segment profit [ratio]	47	[5.3%]	87	[9.1%]	40	83.7%
Adjustment	Segment revenue	(58)		(76)		(17)	–
	Segment profit	(90)		(151)		(60)	–
Total	Revenue	5,776		6,698		921	16.0%
	EBITDA [margin]	1,521	[26.3%]	1,679	[25.1%]	158	10.4%

(Note) EBITDA is an objective indicator for judging the achievement of the JMDC Group's (the "Group's") management policies and strategies or management objectives. The Group uses EBITDA to measure the performance of each segment and believes that it is a useful and necessary measure to assess the Group's performance more effectively. The formulas for calculating EBITDA and EBITDA margin are as follows.
- EBITDA: Operating profit + Depreciation and amortization ± Other income and/or expenses
- EBITDA margin: EBITDA / Revenue x 100

In the three months ended June 30, 2023, the Company transferred all shares of Unike Software Research Co., Ltd., a component of the Company's Dispensing Pharmacy Support segment, and its management purpose company to the Company's business partner EM Systems Co., Ltd. Due to this

transfer, etc., operating profit increased significantly on a year-on-year basis as a result of recording ¥1,458 million as other income.

Results by each segment are as follows.

Healthcare-Big Data

The Group possesses the largest scale of healthcare big data in Japan that is available for public through data anonymization of receipts (admitted patients, day patients, prescriptions), medical examinations and member records received from health insurance associations. During the three months ended June 30, 2023, the number of contracted health insurance associations and the annual transaction value per customer at pharmaceutical and insurance companies which the Company uses and utilizes, each continued to increase on a year-on-year basis, and the business is continuing to expand.

Moreover, the Pep Up health information platform developed by the Company is used to generate individualized advice and display risk of diseases for every individual user based on the above healthcare-big data. The number of IDs issued for Pep Up continued to expand during the fiscal year ending March 31, 2024.

In addition to the above-mentioned business expansion, the Company gathered 148 companies and organizations that will work to implemented health management that exceeds industry organizations, and commenced full-scale operations for the “Health & Productivity Management Alliance” in June 2023. This alliance aims to have 300 companies participating within fiscal 2023, and plans to jointly create solutions in order to shape and strive for results in health management and realize implementation for the industry by carrying out initiatives, such as setting evaluation indicators for health management, creating health management assessments based on data analysis, building an information platform for various solutions, and holding study sessions and seminars.

As a result, segment revenue for the three months ended June 30, 2023 was ¥4,497 million and segment profit (segment EBITDA) was ¥1,294 million.

Tele-medicine

The Group has the biggest platform for radiologists in Japan. In the three months ended June 30, 2023, revenue increased on a year-on-year basis as a result of the continued increase in the number of medical institutions utilizing remote image interpretation services.

We continue to take measures to expand our business, including adding functions to “AI-RAD,” an artificial intelligence engine platform that assists in diagnostic imaging, and preparations for full-scale business development overseas, including in China.

As a result, segment revenue for the three months ended June 30, 2023 was ¥1,307 million and segment profit (segment EBITDA) was ¥448 million.

Dispensing Pharmacy Support

During the three months ended June 30, 2023, we worked to cultivate new customers while securing replacement demand from existing customers. In the environment surrounding dispensing pharmacies, the intensity of competition has increased as digitalization has advanced.

Amid the above-mentioned situation, the Company transferred all shares of Unike Software Research Co., Ltd., a component of the Company’s Dispensing Pharmacy Support segment, and its management purpose company to the Company’s business partner EM Systems Co., Ltd. in June 2023. Due to this transfer, the Company will provide even higher quality services by further acceleration initiatives taken thus far by both companies, and make a splash in the pharmacy market, which will increase the Company’s market share.

As a result, segment revenue for the three months ended June 30, 2023 was ¥969 million and segment profit (segment EBITDA) was ¥87 million.

As a result of the above, for the three months ended June 30, 2023, revenue increased to ¥6,698 million, operating profit to ¥2,546 million, and EBITDA to ¥1,679 million. Adjustments to reconcile EBITDA to operating profit are as follows.

(Reconciliation of EBITDA to operating profit)

(Millions of yen)

	10th fiscal year Three months ended June 30, 2022	11th fiscal year Three months ended June 30, 2023
EBITDA	1,521	1,679
Depreciation and amortization	(444)	(551)
Other income	19	1,458
Other expenses	(14)	(40)
Operating profit	1,081	2,546

(2) Explanation of financial position

(i) Assets, liabilities and equity

Assets

Assets at the end of the first quarter under review were ¥97,523 million, a decrease of ¥1,043 million compared with the end of the fiscal year ended March 31, 2023. Major changes included an increase of ¥1,184 million in goodwill as a result of the acquisition of new consolidated subsidiaries, etc., and a decrease of ¥1,654 million in trade and other receivables.

Liabilities

Liabilities at the end of the first quarter under review were ¥31,682 million, a decrease of ¥2,360 million compared with the end of the fiscal year ended March 31, 2023. This was primarily due to decreases of ¥661 million in income taxes payable due to their payment and ¥924 million in trade and other payables.

Equity

Equity at the end of the first quarter under review was ¥65,841 million, an increase of ¥1,316 million compared with the end of the fiscal year ended March 31, 2023. This was primarily due to the recording of ¥2,040 million in profit while dividends of ¥754 million were recorded.

(ii) Cash flows

Cash and cash equivalents (“cash”) at the end of the first quarter under review was ¥23,029 million, an increase of ¥247 million compared with the end of the fiscal year ended March 31, 2023.

The respective cash flow positions for the three months ended June 30, 2023, and the factors thereof are as follows.

Cash flows from operating activities

During the three months ended June 30, 2023, profit before tax was ¥2,552 million, an increase of ¥1,432 million on a year-on-year basis. Inflows included depreciation and amortization of ¥551 million and a decrease in trade and other receivables of ¥1,509 million. At the same time, there were outflows of ¥1,458 million from other income, ¥1,191 million from income taxes paid, and ¥701 million from a decrease in trade and other payables. As a result, net cash provided by operating activities was ¥1,439 million. Although other income had been included in other up to the end of the fiscal year ended March 31, 2023, after a review due to the increased materiality, they are presented separately from the first quarter under review. The consolidated financial statements for the previous fiscal year have been reclassified to reflect this change in presentation.

Cash flows from investing activities

Net cash used in investing activities was ¥1,465 million. This was primarily due to purchase of shares of subsidiaries resulting in change in scope of consolidation of ¥1,450 million.

Cash flows from financing activities

Net cash provided by financing activities was ¥273 million. This was primarily due to the recording of ¥1,701 million in proceeds from short-term borrowings, despite recording of ¥751 million in dividends paid and ¥529 million in repayments of long-term borrowings.

(3) Explanation of consolidated earnings forecasts and other forward-looking statements

The Company has revised its consolidated earnings forecasts for the fiscal year ending March 31, 2024 as follows from those that were announced on May 9, 2023.

	Revenue	Operating profit	Profit before tax	Profit	Profit attributable to owners of parent	Basic earnings per share
	Millions of yen	Millions of yen	Millions of yen	Millions of yen	Millions of yen	Yen
Previously announced forecast (A)	35,000	7,600	7,550	7,550	5,300	84.25
Revised forecast (B)	33,000	8,800	8,750	8,750	6,500	103.32
Increase (Decrease) (B-A)	(2,000)	+1,200	+1,200	+1,200	+1,200	–
Increase (Decrease) percentage (%)	(5.7)	+15.8	+15.9	+15.9	+22.6	–
(Reference) Actual results for the fiscal year ended March 31, 2023	27,809	5,926	5,876	4,274	4,267	71.17

(Reasons for revisions)

As for the consolidated earnings forecasts, as stated in the “Notice of Changes in Subsidiaries (Transfer of Shares)” announced on June 26, 2023, the Company reflected the impact from transferring all shares of its consolidated subsidiary Unike Software Research and the said company’s management purpose company to EM Systems Co., Ltd.

The impact of the Health & Productivity Management Alliance, which started in June 2023, on operating results continues to not be included in the consolidated earnings forecasts above as it cannot currently be rationally estimated.

2. Condensed quarterly consolidated financial statements and significant notes thereto

(1) Condensed quarterly consolidated statement of financial position

(Millions of yen)

	As of March 31, 2023	As of June 30, 2023
Assets		
Current assets		
Cash and cash equivalents	22,782	23,029
Trade and other receivables	11,241	9,586
Other financial assets	3,340	3,240
Inventories	275	189
Other current assets	601	616
Total current assets	38,240	36,662
Non-current assets		
Property, plant and equipment	10,772	10,869
Goodwill	39,824	41,008
Intangible assets	5,922	5,300
Other financial assets	1,597	1,667
Deferred tax assets	2,057	1,886
Other non-current assets	152	129
Total non-current assets	60,326	60,861
Total assets	98,567	97,523
Liabilities and equity		
Liabilities		
Current liabilities		
Borrowings	994	975
Trade and other payables	5,790	4,865
Lease liabilities	846	836
Income taxes payable	1,201	540
Contract liabilities	2,066	2,214
Other current liabilities	1,317	1,132
Total current liabilities	12,216	10,564
Non-current liabilities		
Borrowings	11,935	11,680
Lease liabilities	6,623	6,780
Retirement benefit liability	322	126
Provisions	692	421
Deferred tax liabilities	730	724
Contract liabilities	1,520	1,383
Total non-current liabilities	21,825	21,117
Total liabilities	34,042	31,682
Equity		
Share capital	23,994	24,008
Capital surplus	27,211	27,225
Treasury shares	(2)	(2)
Other components of equity	28	26
Retained earnings	13,308	14,597
Total equity attributable to owners of parent	64,539	65,856
Non-controlling interests	(14)	(14)
Total equity	64,524	65,841
Total liabilities and equity	98,567	97,523

(2) Condensed quarterly consolidated statement of profit or loss and condensed quarterly consolidated statement of comprehensive income

Condensed quarterly consolidated statement of profit or loss

(Millions of yen)

	Three months ended June 30, 2022	Three months ended June 30, 2023
Revenue	5,776	6,698
Cost of sales	2,455	2,999
Gross profit	3,320	3,698
Selling, general and administrative expenses	2,244	2,570
Other income	19	1,458
Other expenses	14	40
Operating profit	1,081	2,546
Finance income	54	20
Finance costs	16	14
Profit before tax	1,120	2,552
Income tax expense	360	512
Profit	759	2,040
Profit attributable to		
Owners of parent	765	2,040
Non-controlling interests	(6)	(0)
Profit	759	2,040
Earnings per share		
Basic earnings per share (Yen)	13.55	32.42
Diluted earnings per share (Yen)	12.73	31.07

Condensed quarterly consolidated statement of comprehensive income

(Millions of yen)

	Three months ended June 30, 2022	Three months ended June 30, 2023
Profit	759	2,040
Other comprehensive income		
Items that will not be reclassified to profit or loss		
Financial assets measured at fair value through other comprehensive income	4	3
Total of items that will not be reclassified to profit or loss	4	3
Items that may be reclassified to profit or loss		
Exchange differences on translation of foreign operations	(1)	(0)
Total of items that may be reclassified to profit or loss	(1)	(0)
Other comprehensive income, net of tax	3	3
Comprehensive income	762	2,043
Comprehensive income attributable to		
Owners of parent	769	2,043
Non-controlling interests	(6)	(0)
Comprehensive income	762	2,043

(3) Condensed quarterly consolidated statement of changes in equity

Three months ended June 30, 2022 (from April 1 to June 30, 2022)

(Millions of yen)

	Equity attributable to owners of parent					
				Other components of equity		
	Share capital	Capital surplus	Treasury shares	Exchange differences on translation of foreign operations	Financial assets measured at fair value through other comprehensive income	Share acquisition rights
Balance as of April 1, 2022	9,091	12,483	(2)	(4)	–	21
Profit	–	–	–	–	–	–
Other comprehensive income	–	–	–	(1)	4	–
Total comprehensive income	–	–	–	(1)	4	–
Exercise of share acquisition rights	21	21	–	–	–	(0)
Dividends	–	–	–	–	–	–
Increase (decrease) by business combination	–	–	–	–	–	–
Transfer to retained earnings	–	–	–	–	(4)	–
Total transactions with owners	21	21	–	–	(4)	(0)
Balance as of June 30, 2022	9,113	12,504	(2)	(5)	–	21

	Equity attributable to owners of parent			Non-controlling interests	Total
	Other components of equity	Retained earnings	Total		
	Total				
Balance as of April 1, 2022	17	9,580	31,170	(5)	31,165
Profit	–	765	765	(6)	759
Other comprehensive income	3	–	3	–	3
Total comprehensive income	3	765	769	(6)	762
Exercise of share acquisition rights	(0)	–	41	–	41
Dividends	–	(565)	(565)	–	(565)
Increase (decrease) by business combination	–	–	–	(15)	(15)
Transfer to retained earnings	(4)	4	–	–	–
Total transactions with owners	(4)	(560)	(523)	(15)	(539)
Balance as of June 30, 2022	15	9,785	31,416	(26)	31,389

Three months ended June 30, 2023 (from April 1 to June 30, 2023)

(Millions of yen)

	Equity attributable to owners of parent					
				Other components of equity		
	Share capital	Capital surplus	Treasury shares	Exchange differences on translation of foreign operations	Financial assets measured at fair value through other comprehensive income	Share acquisition rights
Balance as of April 1, 2023	23,994	27,211	(2)	(4)	–	32
Profit	–	–	–	–	–	–
Other comprehensive income	–	–	–	(0)	3	–
Total comprehensive income	–	–	–	(0)	3	–
Exercise of share acquisition rights	14	14	–	–	–	(0)
Purchase of treasury shares	–	–	(0)	–	–	–
Dividends	–	–	–	–	–	–
Transfer to retained earnings	–	–	–	–	(3)	–
Total transactions with owners	14	14	(0)	–	(3)	(0)
Balance as of June 30, 2023	24,008	27,225	(2)	(5)	–	31

	Equity attributable to owners of parent			Non-controlling interests	Total
	Other components of equity	Retained earnings	Total		
	Total				
Balance as of April 1, 2023	28	13,308	64,539	(14)	64,524
Profit	–	2,040	2,040	(0)	2,040
Other comprehensive income	3	–	3	–	3
Total comprehensive income	3	2,040	2,043	(0)	2,043
Exercise of share acquisition rights	(0)	–	28	–	28
Purchase of treasury shares	–	–	(0)	–	(0)
Dividends	–	(754)	(754)	–	(754)
Transfer to retained earnings	(3)	3	–	–	–
Total transactions with owners	(4)	(751)	(726)	–	(726)
Balance as of June 30, 2023	26	14,597	65,856	(14)	65,841

(4) Condensed quarterly consolidated statement of cash flows

(Millions of yen)

	Three months ended June 30, 2022	Three months ended June 30, 2023
Cash flows from operating activities		
Profit before tax	1,120	2,552
Depreciation and amortization	444	551
Other income	(19)	(1,458)
Decrease (increase) in trade and other receivables	438	1,509
Decrease (increase) in inventories	(25)	6
Increase (decrease) in trade and other payables	(181)	(701)
Other	342	177
Subtotal	2,119	2,636
Interest and dividends received	0	0
Interest paid	(13)	(5)
Income taxes paid	(1,016)	(1,191)
Net cash provided by (used in) operating activities	1,089	1,439
Cash flows from investing activities		
Purchase of property, plant and equipment	(180)	(62)
Purchase of intangible assets	(318)	(263)
Payments for loans receivable	(150)	–
Purchase of shares of subsidiaries resulting in change in scope of consolidation	(2,729)	(1,450)
Proceeds from sale of shares of subsidiaries resulting in change in scope of consolidation	–	273
Other	132	37
Net cash provided by (used in) investing activities	(3,245)	(1,465)
Cash flows from financing activities		
Proceeds from short-term borrowings	–	1,701
Proceeds from long-term borrowings	–	28
Repayments of long-term borrowings	(198)	(529)
Repayments of lease liabilities	(189)	(223)
Proceeds from exercise of share acquisition rights	41	48
Dividends paid	(563)	(751)
Other	0	(0)
Net cash provided by (used in) financing activities	(909)	273
Net increase (decrease) in cash and cash equivalents	(3,065)	247
Cash and cash equivalents at beginning of period	13,192	22,782
Effect of exchange rate changes on cash and cash equivalents	0	(0)
Cash and cash equivalents at end of period	10,128	23,029

(5) Notes to condensed quarterly consolidated financial statements

Notes on going concern assumption

Not applicable.

Segment information

(1) Overview of reportable segments

The Group's reportable segments are components of the Group for which discrete financial information is available, and whose operating results are regularly reviewed by the Board of Directors to make decisions about managerial resources to be allocated to the segments and assess their performances. The Group considers similarities in the nature of the services it provides and has three reportable segments: "Healthcare-Big Data," "Tele-medicine," and "Dispensing Pharmacy Support."

The main businesses and main services included in each reportable segment are as follows.

Reportable segments	Main businesses	Main services
Healthcare-Big Data	Business for industry Business for payers and individuals Business for medical service providers	Development and provision of medical databases (receipts, pharmaceuticals, etc.) and analysis of medical big data
Tele-medicine	Tele-medicine business	Remote image interpretation matching service and ASP service for remote image interpretation system
Dispensing Pharmacy Support	Dispensing pharmacy support business	Development and sales of business systems for dispensing pharmacies

(2) Information about reportable segments

Revenue and operating results by reportable segments of the Group are as follows.

Intersegment revenues are based on negotiated transaction prices, taking into account market prices and production costs. Segment profits are EBITDA (Operating profit + Depreciation and amortization ± Other income/expenses).

Three months ended June 30, 2022 (from April 1 to June 30, 2022)

(Millions of yen)

	Reportable segments				Adjustments (Note)	Consolidated
	Healthcare-Big Data	Tele-medicine	Dispensing Pharmacy Support	Total		
Revenue						
Revenue from external customers	3,731	1,175	869	5,776	–	5,776
Intersegment revenue	17	–	41	58	(58)	–
Total	3,749	1,175	910	5,835	(58)	5,776
Segment profit EBITDA	1,124	439	47	1,611	(90)	1,521

Note: Adjustments include elimination of intersegment transactions and corporate expenses.

Three months ended June 30, 2023 (from April 1 to June 30, 2023)

(Millions of yen)

	Reportable segments				Adjustments (Note)	Consolidated
	Healthcare-Big Data	Tele-medicine	Dispensing Pharmacy Support	Total		
Revenue						
Revenue from external customers	4,472	1,307	919	6,698	–	6,698
Intersegment revenue	25	–	50	76	(76)	–
Total	4,497	1,307	969	6,774	(76)	6,698
Segment profit EBITDA	1,294	448	87	1,831	(151)	1,679

Note: Adjustments include elimination of intersegment transactions and corporate expenses.

A reconciliation of EBITDA to profit before tax is as follows.

(Millions of yen)

	Three months ended June 30, 2022	Three months ended June 30, 2023
EBITDA	1,521	1,679
Depreciation and amortization	(444)	(551)
Other income	19	1,458
Other expenses	(14)	(40)
Operating profit	1,081	2,546
Finance income	54	20
Finance costs	(16)	(14)
Profit before tax	1,120	2,552

Significant subsequent events

Not applicable.